Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 7/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MC4R | P32245 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | GPR183 | P32249 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 2/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18054024 | 0.87 | CHKA (0.59) | CHKALMNAALDH1A1MC4RHTT | |
| SCHEMBL12891510 | 0.86 | ALDH1A1 (0.69) | CHKALMNAALDH1A1MC4RHTT | |
| SCHEMBL24746120 | 0.85 | ALDH1A1 (0.72) | ALDH1A1HTTGPR183KDM4E | |
| SCHEMBL14609609 | 0.84 | LMNA (0.58) | CHKALMNAALDH1A1MC4RCA2 | |
| SCHEMBL26118682 | 0.83 | ALDH1A1 (0.51) | CHKALMNAALDH1A1HTTGPR183 | |
| SCHEMBL10042372 | 0.83 | ALDH1A1 (0.51) | CHKAALDH1A1HTTGPR183KDM4E | |
| SCHEMBL414890 | 0.82 | KDM4E (0.68) | CHKALMNAALDH1A1MC4RHTT | |
| SCHEMBL29468844 | 0.82 | KDM4E (0.68) | CHKALMNAALDH1A1MC4RHTT | |
| SCHEMBL17724130 | 0.82 | HRH3 (0.54) | ALDH1A1HTTGPR183NCF1KDM4E | |
| SCHEMBL16178546 | 0.80 | LMNA (0.62) | CHKALMNAALDH1A1MC4RCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119692-B2 | Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100286125-A1 | Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286125-A1 | Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning | ANTXR2, ABAT, BAX | CHKA 3055/4885LMNA 2360/4885ALDH1A1 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.